Advertisement

Related Videos

Welcome and Introduction to Vi3C

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Advertisement

Advertisement




May
01
Today In Oncology
Melanoma Gut Microbiome May Help Predict Recurrence After Immunotherapy
Association of Body Size and Bladder Cancer Risk
5-Year Follow-Up From AUGMENT Lenalidomide Plus Rituximab in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
Can PFAS Exposure Raise ALL Risk?
Atezolizumab in Alveolar Soft Part Sarcoma Long-Term Follow-up
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo